Roche, the world’s largest maker of cancer drugs, will pay $74 a share for InterMune, an unprofitable biotechnology company that’s awaiting US approval of its biggest drug.Photograph: STEFFEN SCHMIDT/EPA

Roche Holding, the world’s largest maker of cancer drugs, is strengthening its portfolio of medicines for respiratory ailments with an agreement to bu(...)

Peter Diamandis, chairman and chief executive of the X Prize Foundation: “Most CEOs today are focused on quarterly returns . . . They are unaware of [what is coming down the track] which will be massively disruptive”. Photograph: Nadine Rupp/Getty Images

Dr Peter Diamandis is a man who sees the future in the present. His mission he says is “to open the space frontier for humanity” and he believes it is(...)

Biotech fever is spreading to Europe from the United States with a successful stock market debut for a cat allergy company in Britain seen as a(...)

 Christoph Franz (left), designated chairman of the board, speaks to Franz B Humer, outgoing chairman of the board of Roche, during the general assembly of Swiss pharmaceutical company Roche Holding AG in Basel, Switzerland, yesterday. Photograph: EPA/Patrick Straub

Roche’s new chairman has signalled his intention to follow his predecessor’s tight-fisted approach toward acquisitions even now that the drugma(...)

Larry Page: The new company will focus on issues such as decreased mobility and mental agility in addition to life-threatening diseases. Photograph:  Emmanuel Dunand/AFP/Getty Images

Having mapped the earth, developed “smart glasses” and cars that drive by themselves, the next big issue that Google plans to target is old age. In a (...)

The headquarters of Roche Holding  in Basel, Switzerland. Photographer: Peter Frommenwiler/Bloomberg

Roche will halt development of a diabetes drug partly because of its undesired side-effects, marking another high-profile setback for the Swiss compa(...)

Pablo Legorreta, chief executive and founder of Royalty Pharma

Pablo Legorreta is down but not out. The man behind the high profile and often crabby campaign to acquire Ireland’s largest indigenous pharma group El(...)